The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 17, 2020
Filed:
Jul. 07, 2017
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Universite DE LA Reunion Saint Denis, Saint Denis, FR;
Institut DE Recherche Pour Le Développement (Ird), Marseilles, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Gilles Gadea, La Réunion, FR;
Michael Girardot, Castelnau-le-Lez, FR;
Philippe Despres, La Réunion, FR;
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris, FR;
UNIVERSITE DE LA REUNION SAINT DENIS, St. Denis, FR;
INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD), Marseilles, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
Abstract
The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.